MA26629A1 - Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production - Google Patents

Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production

Info

Publication number
MA26629A1
MA26629A1 MA25577A MA25577A MA26629A1 MA 26629 A1 MA26629 A1 MA 26629A1 MA 25577 A MA25577 A MA 25577A MA 25577 A MA25577 A MA 25577A MA 26629 A1 MA26629 A1 MA 26629A1
Authority
MA
Morocco
Prior art keywords
sildeenfil
pharmaceutical preparation
orely
delenited
production
Prior art date
Application number
MA25577A
Other languages
English (en)
Inventor
Francis Dolan Thomas
Carol Gratlin Hausberge Angela
Bell-Huff Cristi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26629A1 publication Critical patent/MA26629A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)

Abstract

L'INVENTION CONCERNE UNE PRÉPARATION PHARMACEUTIQUE, à DÉLITEMENT ORAL, COMPRENANT DU SILDÉNAFIL SOUS FORME DE BASE LIBRE CONJOINTEMENT AVEC UN SUPPORT PHARMACEUTIQUEMENT ACCEPTABLE. ELLE CONCERNE ÉGALEMENT UN PROCÉDÉ POUR SA PRÉPARATION EN UTILISANT UN LIANT HYDRSOLUBLE POUVANT FONDRE, AU MOINS UN EXCIPIENT ET LE SILDÉNAFIL SOUS FORME DE BASE LIBRE. -APPLICATION : UTILISATION DE CETTE PRÉPARATION POUR LE TRAITEMENT DE DYSFONCTIONNEMENTS SUXUELS MASCULINS ET FÉMININS.
MA25577A 1998-05-15 1999-05-12 Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production MA26629A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8564698P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
MA26629A1 true MA26629A1 (fr) 2004-12-20

Family

ID=22193027

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25577A MA26629A1 (fr) 1998-05-15 1999-05-12 Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production

Country Status (32)

Country Link
US (1) US20020002172A1 (fr)
EP (1) EP0960621A3 (fr)
JP (1) JPH11349483A (fr)
KR (1) KR19990088249A (fr)
CN (1) CN1251758A (fr)
AP (1) AP9901534A0 (fr)
AR (1) AR016481A1 (fr)
AU (1) AU753478B2 (fr)
BG (1) BG103396A (fr)
BR (1) BR9902086A (fr)
CA (1) CA2272042A1 (fr)
CO (1) CO5060503A1 (fr)
DZ (1) DZ2786A1 (fr)
EA (1) EA002830B1 (fr)
GT (1) GT199900061A (fr)
HN (1) HN1999000066A (fr)
HR (1) HRP990144A2 (fr)
HU (1) HUP9901606A2 (fr)
ID (1) ID23299A (fr)
IS (1) IS5046A (fr)
MA (1) MA26629A1 (fr)
NO (1) NO992339L (fr)
NZ (1) NZ335772A (fr)
OA (1) OA11040A (fr)
PA (1) PA8472901A1 (fr)
PE (1) PE20000546A1 (fr)
PL (1) PL333118A1 (fr)
SG (1) SG79255A1 (fr)
SK (1) SK61599A3 (fr)
TR (1) TR199901077A3 (fr)
YU (1) YU21999A (fr)
ZA (1) ZA993338B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020033A1 (fr) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
EP1171134A4 (fr) * 1999-03-16 2005-01-05 Pentech Pharmaceuticals Inc Liberation controlee de sildenafil administre par voie sublinguale ou orale
WO2000057857A1 (fr) * 1999-03-25 2000-10-05 Yuhan Corporation Comprimé à administrer oralement se désagrégeant rapidement
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
CN1264574C (zh) * 2000-09-06 2006-07-19 田边制药株式会社 口服制剂
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
IN192750B (fr) * 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6544552B2 (en) * 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1226818A1 (fr) * 2001-01-26 2002-07-31 Pfizer Products Inc. Formulation pharmaceutique présentant des propriétés de cohesion et de compressibilité améliorées
WO2002089808A1 (fr) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Nouvelle utilisation d'imidazotriazinones substituees 2-phenyl
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
JPWO2003028706A1 (ja) * 2001-09-28 2005-01-13 株式会社三和化学研究所 有核型速溶崩壊性成型品
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
WO2006016530A1 (fr) * 2004-08-10 2006-02-16 Translational Research, Ltd. Composition transnasale dont l’action est immédiate et l’absorbabilité est élevée
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CA2612917A1 (fr) * 2005-06-23 2007-01-04 Schering Corporation Formulations orales a absorption rapide d'inhibiteurs de la pde5
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CN101674728A (zh) * 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
WO2008151734A1 (fr) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Inhibiteurs de la phosphodiestérase (pde) destinés au traitement des troubles de l'audition
FR2932682B1 (fr) * 2008-06-23 2013-07-12 Bionetwork Nouvelles formes pharmaceutiques a effet rapide et les utilisations des compositions pharmaceutiques ainsi obtenus.
US8617588B2 (en) 2009-03-09 2013-12-31 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
WO2010131486A1 (fr) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions pharmaceutiques intranasales avec pharmacocinétique améliorée
WO2011013003A2 (fr) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Granisétron pour administration intranasale et applicateur nasal
WO2011030351A2 (fr) 2009-09-03 2011-03-17 Rubicon Research Private Limited Compositions pharmaceutiques au goût masqué
EP2338474A1 (fr) * 2009-12-23 2011-06-29 Ratiopharm GmbH Comprimé orodispersible contenant une base de sidénafil compactée
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
BR112013020237A2 (pt) * 2011-02-11 2021-03-16 Ctc Bio, Inc. Processo para preparar um filme contendo base livre de sildenafila e filme contendo base livre de sildenafila
KR101418406B1 (ko) * 2011-08-24 2014-07-10 한미약품 주식회사 실데나필 유리 염기를 포함하는 구강 붕해정
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN105769887B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种复方果糖二磷酸钠果糖口崩片及其制备方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法
WO2025048919A1 (fr) * 2023-08-30 2025-03-06 Dow Global Technologies Llc Mélanges d'excipients séchés par pulvérisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE19532142A1 (de) * 1995-08-31 1997-03-06 Siemens Ag Verfahren und Vorrichtung zur Regelung eines vierdimensionalen Vektors einer Strecke mittels eines wertediskreten Stellgliedes mit begrenzter Schaltfrequenz
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
EP1171134A4 (fr) * 1999-03-16 2005-01-05 Pentech Pharmaceuticals Inc Liberation controlee de sildenafil administre par voie sublinguale ou orale

Also Published As

Publication number Publication date
HU9901606D0 (en) 1999-07-28
BR9902086A (pt) 2000-05-02
DZ2786A1 (fr) 2003-12-01
AP9901534A0 (en) 1999-06-30
US20020002172A1 (en) 2002-01-03
EP0960621A2 (fr) 1999-12-01
CN1251758A (zh) 2000-05-03
HN1999000066A (es) 1999-09-29
CO5060503A1 (es) 2001-07-30
NO992339L (no) 1999-11-16
AR016481A1 (es) 2001-07-04
BG103396A (bg) 2000-01-31
PL333118A1 (en) 1999-11-22
SK61599A3 (en) 2000-12-11
YU21999A (sh) 2002-03-18
IS5046A (is) 1999-11-16
HRP990144A2 (en) 2000-02-29
SG79255A1 (en) 2001-03-20
EP0960621A3 (fr) 2000-01-05
AU753478B2 (en) 2002-10-17
CA2272042A1 (fr) 1999-11-15
TR199901077A2 (en) 1999-12-21
TR199901077A3 (tr) 1999-12-21
OA11040A (en) 2003-01-01
JPH11349483A (ja) 1999-12-21
PE20000546A1 (es) 2000-07-07
ZA993338B (en) 2000-11-14
PA8472901A1 (es) 2000-09-29
GT199900061A (es) 2000-10-14
ID23299A (id) 2000-04-05
NZ335772A (en) 2000-12-22
HUP9901606A2 (en) 2002-09-28
NO992339D0 (no) 1999-05-14
KR19990088249A (ko) 1999-12-27
EA199900373A2 (ru) 1999-12-29
EA199900373A3 (ru) 2000-08-28
AU2812699A (en) 1999-11-25
EA002830B1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
MA26629A1 (fr) Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
DZ2237A1 (fr) 4(3H)-Quinazolinones 2,3-disubstituées nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA27037A1 (fr) Amides d'acide anthranilique avec une chaine laterale heteroarylsulfonyle, procede pour leur fabrication, leur utilisation comme medicament et comme agent de diagnostic ainsi que les preparations pharmaceutiques en contenant
TWI256891B (en) 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
CA2318128A1 (fr) Compositions liquides orales
BR0213355A (pt) composições farmacêuticas
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
EA200000246A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
ZA965235B (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
PT991653E (pt) Novos compostos
MA26747A1 (fr) Composes inhibiteurs de recepteurs de nmda, leurs utilisations dans le traitement de troubles neuronaux et leurs preparations
PL331822A1 (en) Application of a chelating agent clioquinole in production of a pharmaceutic agent designed for use in treatment of alzheimer disease
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.
MX9505065A (es) Composicion farmaceutica, aplicable oralmente.
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
DZ3079A1 (fr) Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
BR0209845A (pt) Formas de dosagem de oxcarbazepina e processo para a preparação das mesmas
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP2452684A3 (fr) Micelles
EP1637139A3 (fr) Nouvelle utilisation de composés inhibiteurs de la protéase du VIH
EP0670166A3 (fr) Compositions pharmaceutiques administrables par voie buccale.
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
NO20033318L (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav